← 返回

肿瘤浸润原代 NK 细胞的体内 AAV-SB-CRISPR 筛选鉴定 CAR-NK 疗法的遗传检查点

英文原题:In vivo AAV-SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy.

查看英文原题

In vivo AAV-SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy.

PubMed 2024/06/25(内容时间) Nat Biotechnol Q1 · IF 44.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

自然杀伤(NK)细胞具有抗肿瘤的临床潜力;然而,多种限制因素阻碍了 NK 细胞疗法的成功。在此,我们在四种实体瘤小鼠模型中,利用体内腺相关病毒(AAV)-SB(Sleeping Beauty)-CRISPR(成簇规律间隔短回文重复序列)筛选,对肿瘤浸润 NK(TINK)细胞进行了无偏功能图谱绘制。与此同时,我们刻画了 TINK 细胞的单细胞转录组图谱,从中鉴定出此前未被探索的 NK 细胞亚群以及差异表达的 TINK 基因。作为一个汇聚性命中靶点,CALHM2 敲除(KO)的 NK 细胞在小鼠原代 NK 细胞和人嵌合抗原受体(CAR)-NK 细胞中均表现出增强的细胞毒性和肿瘤浸润能力。CALHM2 mRNA 可逆转 CALHM2-KO 表型。在人原代 NK 细胞中敲除 CALHM2 可增强其细胞毒性、脱颗粒和细胞因子产生。转录组谱分析揭示了在基线和刺激条件下 CALHM2-KO 所改变的基因和通路。在对未修饰 CAR-NK 细胞耐药的实体瘤模型中,CALHM2-KO CAR-NK 细胞在体内展现出强效的抗肿瘤疗效。这些数据鉴定了天然限制 NK 细胞功能的内源性遗传检查点,并证明了利用 CALHM2 KO 工程化改造以增强基于 NK 细胞的免疫疗法的可行性。

展开英文摘要原文

Natural killer (NK) cells have clinical potential against cancer; however, multiple limitations hinder the success of NK cell therapy.

Here, we performed unbiased functional mapping of tumor-infiltrating NK (TINK) cells using in vivo adeno-associated virus (AAV)-SB (Sleeping Beauty)-CRISPR (clustered regularly interspaced short palindromic repeats) screens in four solid tumor mouse models. In parallel, we characterized single-cell transcriptomic landscapes of TINK cells, which identified previously unexplored subpopulations of NK cells and differentially expressed TINK genes. As a convergent hit, CALHM2-knockout (KO) NK cells showed enhanced cytotoxicity and tumor infiltration in mouse primary NK cells and human chimeric antigen receptor (CAR)-NK cells.

CALHM2 mRNA reversed the CALHM2-KO phenotype. CALHM2 KO in human primary NK cells enhanced their cytotoxicity, degranulation and cytokine production. Transcriptomics profiling revealed CALHM2-KO-altered genes and pathways in both baseline and stimulated conditions.

In a solid tumor model resistant to unmodified CAR-NK cells, CALHM2-KO CAR-NK cells showed potent in vivo antitumor efficacy. These data identify endogenous genetic checkpoints that naturally limit NK cell function and demonstrate the use of CALHM2 KO for engineering enhanced NK cell-based immunotherapies.

论文信息

作者
Peng L、Renauer PA、Sferruzza G、Yang L、Zou Y、Fang Z、Park JJ、Chow RD
第一作者单位
Department of Genetics, Yale University School of Medicine, New Haven, CT, USA.United States
通讯作者单位
Department of Genetics, Yale University School of Medicine, New Haven, CT, USA. sidi.chen@yale.edu.United States
期刊
Nature biotechnology2025 May
原文标识
PubMed 38918616 · DOI 10.1038/s41587-024-02282-4